Navigation Links
Initiation of Coverage Informational Review Issued by Scimitar Equity Research
Date:12/17/2007

BOSTON, Dec. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. issues a review on Nventa Biopharmaceuticals Corporation (TSX: NVN) entitled: "A Very Promising Therapeutic and Vaccine Candidate for the Treatment of Diseases Caused by the Human Papillomavirus (HPV)." The analyst research is available on Scimitar's website: http://www.scimitarequity.com.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

About HspE7, Nventa's Lead Product Candidate:

HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.

Scimitar Equity Research, Inc. provides equity research of emerging healthcare companies for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NVN.TO (TSX) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any inve
'/>"/>

SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... SAN FRANCISCO, Calif. , May 28, 2015 /PRNewswire/ ... treatment of cancer, today announced that Sean McCarthy ... the upcoming Jefferies 2015 Global Healthcare Conference ... p.m. EDT on Tuesday, June 2, 2015. Dr. McCarthy ... the company,s Precision cancer immunotherapy and Probody drug conjugate ...
(Date:5/28/2015)... 28, 2015  Shareholder rights law firm Robbins ... officers and directors of Eleven Biotherapeutics, Inc. (NASDAQGM: EBIO) ... is a clinical-stage biopharmaceutical company that engages in ... treat eye diseases, primarily in the ... this press release on the law firm,s Shareholder ...
(Date:5/28/2015)... Eli Lilly and Company (NYSE: LLY ) and Incyte ... June 11 to discuss data from the first two pivotal ... two trials, RA-BEACON and RA-BUILD, will be presented on June ... in Rome, Italy . The ... Time. The live audio webcast can be accessed through a ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3
... ... Clinical Duration, CAMBRIDGE, Mass., March 10 ... large, multicenter,observational study that investigated the long-term durability of,Carticel(R) (autologous cultured ... the articular cartilage of their,knee. These findings revealed that almost 90 ...
... The,Journal of the American College of Cardiology has ... Performance of PTCA in,Patients Without Documented Ischemia) as one ... in 2007, according to an article entitled,"Highlights of the ... al. (JACC,Vol. 51, No. 4, 2008 January 29, 2008:490-512), ...
Cached Medicine Technology:Genzyme Announces Presentation of New Positive Data on Carticel(R) 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 3Genzyme Announces Presentation of New Positive Data on Carticel(R) 4Genzyme Announces Presentation of New Positive Data on Carticel(R) 5Genzyme Announces Presentation of New Positive Data on Carticel(R) 6JACC Identifies DEFER with 5-year Outcomes as Landmark Trial 2
(Date:5/28/2015)... AMVETS leaders this week congratulated AMVETS ... Davis of Newark, Del. AMVETS National Commander Larry Via ... the $10,000 sweepstakes grand prize. , AMVETS selected the ... around the country for prizes ranging from $500 to ... May 21 at the AMVETS National Headquarters in Lanham, ...
(Date:5/28/2015)... Ross A. Clevens, MD, FACS, ... Teresa Beard as the new marketing director for Clevens ... oversee all marketing and promotional events for the practice. ... and developing compelling marketing strategies to achieve targeted results. ... served as guest communication manager at the Walt Disney ...
(Date:5/28/2015)... May 28, 2015 As the summer approaches, ... keep cool. It’s important to make safety a top priority, ... some swimming tips. , According to the Centers for Disease ... United States, not including boating incidents. Additionally, the National Safety ... children ages 1 to 4. , Amica is sharing ...
(Date:5/28/2015)... 2015 ISMETT , a leading transplant ... the Sicilian economy by €132.5 million in expenditure in 2013, ... more than €73 million by retaining patients who otherwise would ... new study by the Battelle Memorial Institute. At the same ... and advanced health care management that is transforming Sicily into ...
(Date:5/28/2015)... Altima Technologies, Inc., the maker of popular ... diagramming data center assets and audio-video devices, recently ... , Manufacturer / Device Model, EMC VMAX, ... Cabinet, Middle Atlantic Products RSH Series, Nokia Siemens ... America MM Series, Extron Electronics SW Series, Crestron ...
Breaking Medicine News(10 mins):Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Clevens Face and Body Specialists Welcomes Teresa Beard as Marketing Director 2Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2
... orthopaedic team provides life-changing hip and knee replacements to ... Sept. 8 The Operation Walk Pittsburgh team, consisting ... and Philadelphia recently returned from an extraordinary mission abroad ... 63 successful hip and knee replacements on 50 patients ...
... Sept. 8 Genomma Lab Internacional,S.A.B. de C.V. (BMV: LAB) ... and personal care products companies in Mexico with,expansion into the ... full year of 2009. The Company expects net sales,growth in ... 25%. , The revision of the ...
... , , , ... study conducted at the Temple University School of Medicine and published ... pre-packaged, portion controlled meal plan helped overweight individuals with type 2 ... (a 90-day measure of blood sugar control) by almost a full ...
... , CARMEL, Ind., Sept. 8 Conseco, Inc. ... received the required regulatory approvals for the previously announced transaction ... are coinsuring, with an effective date of January 1, 2009, ... ("Wilton Re"), a Minnesota reinsurance company. , , ...
... Testing for XMRV might help spot more aggressive disease, experts ... study tightens the suspected link between a virus and prostate ... could be an indicator of aggressive tumors that require swift ... moment," stressed Dr. Ila R. Singh, an associate professor of ...
... , , , BEDFORD, Texas, Sept. ... Robert Reiss, the founder and host of one of America,s fastest growing ... the challenges of golf and providing world-class customer service in his upcoming ... Customer Service. Sponsored by The Beryl Institute , the ...
Cached Medicine News:Health News:Operation Walk Pittsburgh Performs Over 63 Free Surgeries in Guatemala 2Health News:Genomma Lab Internacional Revises 2009 Earnings Guidance 2Health News:Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control 2Health News:Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control 3Health News:Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control 4Health News:Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control 5Health News:Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control 6Health News:Conseco Receives Approval to Complete Reinsurance Transaction with Wilton Re 2Health News:Conseco Receives Approval to Complete Reinsurance Transaction with Wilton Re 3Health News:Conseco Receives Approval to Complete Reinsurance Transaction with Wilton Re 4Health News:Conseco Receives Approval to Complete Reinsurance Transaction with Wilton Re 5Health News:Virus May Drive Some Prostate Cancers 2Health News:Virus May Drive Some Prostate Cancers 3Health News:The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 2
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... Techne TC412 is a high performance, high sample ... Features & Benefits include: Flexible block format, ... 8 peltiers, PC networking. Includes a four ... 32 Techne cyclers can be connected and run ...
... a compact design for personal use, yet is able ... up to 32 samples simultaneously. It contains a heating ... to add mineral oil to prevent evaporation of the ... and up to 15 steps can be freely connected ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: